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https://doi.org/10.1186/s13643-019-0962-3RESEARCH Open AccessExercise, or exercise and diet for the
management of polycystic ovary syndrome:
a systematic review and meta-analysis
Chris Kite5,7 , Ian M. Lahart6 , Islam Afzal1 , David R. Broom8 , Harpal Randeva1,2,3,4 , Ioannis Kyrou1,2,3,4 and
James E. Brown1,5*Abstract
Background: Typically, management of PCOS focuses on lifestyle changes (exercise and diet), aiming to alleviate
symptoms, and lower the associated risk of type 2 diabetes and cardiovascular disease. Our objective was to
analyse evidence on the effectiveness of exercise in the management of PCOS, when compared to (i) usual care, (ii)
diet alone, and (iii) exercise combined with diet, and also exercise combined with diet, compared to (i) control or
usual care and (ii) diet alone.
Methods: Relevant databases were searched (June 2017) with no time limit for trial inclusion. Eligible trials
employed a randomised or quasi-randomised design to measure the chronic effects of exercise, or exercise and
diet in women with PCOS.
Results: Searches returned 2390 articles; of those, 27 papers from 18 trials were included. Results are presented as mean
difference (MD) and 95% confidence intervals (95% CI). Compared with control, exercise had a statistical effect on change
from baseline fasting insulin (MD − 2.44 μIU/mL, 95% CIs − 4.24 to − 0.64; very low-quality evidence), HOMA-IR (− 0.57, − 0.99
to − 0.14; very low-quality evidence), total cholesterol (− 5.88mg/dL, − 9.92 to − 1.83; low-quality evidence), LDL cholesterol
(− 7.39mg/dL, − 9.83 to − 4.95; low-quality evidence), and triglycerides (− 4.78mg/dL, − 7.52 to − 2.05; low-quality evidence).
Exercise also improved VO2 max (3.84ml/kg/min, 2.87 to 4.81), waist circumference (− 2.62 cm, − 4.13 to − 1.11), and body
fat percentage (− 1.39%, − 2.61 to − 0.18) when compared with usual care. No effect was found for change value systolic/
diastolic blood pressure, fasting glucose, HDL cholesterol (all low-quality evidence), or waist-to-hip ratio. Many favourable
change score findings were supported by post-intervention value analyses: fasting insulin (− 2.11 μIU/mL, − 3.49 to − 0.73),
total cholesterol (− 6.66 mg/dL, − 11.14 to − 2.17), LDL cholesterol (− 6.91 mg/dL, − 12.02 to − 1.80), and VO2
max (5.01 ml/kg/min, 3.48 to 6.54). Statistically lower BMI (− 1.02 kg/m2, − 1.81 to − 0.23) and resting heart rate
(− 3.26 beats/min − 4.93 to − 1.59) were also revealed in post-intervention analysis. Subgroup analyses revealed the
greatest improvements in overweight/obese participants, and more outcomes improved when interventions were
supervised, aerobic in nature, or of a shorter duration. Based on limited data, we found no differences for any outcome
between the effects of exercise and diet combined, and diet alone. It was not possible to compare exercise vs diet or
exercise and diet combined vs diet.
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Conclusion: Statistically beneficial effects of exercise were found for a range of metabolic, anthropometric, and
cardiorespiratory fitness-related outcomes. However, caution should be adopted when interpreting these findings since
many outcomes present modest effects and wide CIs, and statistical effects in many analyses are sensitive to the
addition/removal of individual trials. Future work should focus on rigorously designed, well-reported trials that make
comparisons involving both exercise and diet.
Systematic review registration: This systematic review was prospectively registered on the Prospero International
Prospective Register of Systematic Reviews (CRD42017062576)
Keywords: Polycystic ovary syndrome, Exercise, Physical activity, Diet, Cardiovascular risk, Insulin resistance,
Cardiorespiratory fitnessTable 1 Eligibility criteria for including studies in this systematic
review
Inclusion criteria:
1. Study design: randomised controlled trials and quasi-randomised
controlled trials.
2. Types of participants: reproductive-aged women with a diagnosis
of polycystic ovary syndrome (PCOS) based on the National
Institute of Health (NIH) diagnostic criteria (1990), the Rotterdam
ESHRE/ASRM (2003) diagnostic criteria or the AE-PCOS Criteria
(2006). We also included trials where the PCOS diagnosis had been
verified by a general practitioner or specialist clinician.
3. Comparators: exercise vs usual care/control, exercise combined
with diet vs usual care/control, exercise combined with diet vs diet
only. Exercise combined with diet vs exercise only, exercise vs diet,
exercise combined with pharmaceutical vs pharmaceutical.
4. All outcomes; expected outcomes included: primary outcomes,
such as blood pressure, fasting blood glucose, insulin and lipid
concentrations; and secondary outcomes, such as body mass index,
cardiorespiratory fitness, testosterone, free androgen index and
health-related quality of life measures.
Exclusion criteria:
1. Study design: case studies, cross sectional and non-randomised
controlled trials.
2. Types of participants: males, adolescent females, post-menopausal
women, women without PCOS
3. Comparators: women with PCOS vs healthy controls,
pharmaceutical vs exercise, pharmaceutical vs diet, diet vs diet,
surgical vs any other condition.Background
Polycystic ovary syndrome (PCOS) is the most common
endocrinopathy in reproductive-aged women, affecting
6–21% (depending on the applied diagnostic criteria) of
this population worldwide [1–3]. PCOS is characterised
by hyperandrogenism and/or chronic anovulation which
can manifest with a range of symptoms (e.g., hirsutism,
acne, oligomenorrhea, and infertility) [4] and is associ-
ated with increased risk of cardiometabolic disease, in-
cluding hypertension, dyslipidaemia, insulin resistance
(IR), and type 2 diabetes mellitus (T2DM) [5]. Moreover,
PCOS is linked to increased psychological morbidity
[e.g., increased risk of stress, depression, low self-esteem,
poor body image, and reduced health-related quality of
life (HRQoL)] [6, 7]. The exact PCOS aetiology is un-
known, but increased adiposity is considered pivotal [8].
Indeed, almost 90% of women with PCOS are over-
weight or obese and even moderate weight loss (e.g., 5%)
may result in clinically meaningful improvements in
hyperandrogenism and menstrual regularity [9–13].
Also, women with PCOS often have more severe IR than
weight-matched women without PCOS [14, 15], whilst
their increased susceptibility to obesity [16] may further
exacerbate IR and the accompanying metabolic [17, 18]
and reproductive [10, 19] dysfunctions. As such, women
with PCOS exhibit increased risk of impaired glucose
tolerance and T2DM regardless of weight and age [20].
As there is currently no curative treatment for PCOS,
management of overweight/obese women with PCOS fo-
cuses on weight loss through regular exercise and diet, aim-
ing to alleviate its clinical manifestations and lower the
related risk of T2DM and cardiovascular disease (CVD)
[21]. Considering the benefits of exercise interventions in
other IR populations independent of weight loss [22–24],
incorporating moderate-intensity exercise in PCOS treat-
ment may be particularly favourable. Existing evidence sup-
ports this; although most exercise trials in women with
PCOS show little or no weight loss [5], exercise can have
favourable effects on IR, body fat distribution, and CVD
risk in these patients [25]. As the number of studies investi-
gating the effects of exercise and diet in PCOS is increasing,it is important to summarise this body of evidence in order
to better inform clinical practice. Therefore, this systematic
review aims to analyse the evidence on the effectiveness of
exercise compared to (i) control or usual care, (ii) diet
alone, and (iii) exercise combined with diet, as well as the
effectiveness of exercise combined with diet compared to
(i) control or usual care and (ii) diet alone.
Methods
This systematic review was prospectively registered on the
Prospero International Prospective Register of Systematic
Reviews (CRD42017062576) and is reported based on the
guidelines of the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [26].
Search methods for identification of studies
Table 1 presents the eligibility criteria for inclusion in
this systematic review. Only trials with women of
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were eligible for inclusion. Eligible trials employed a ran-
domised or quasi-randomised experimental (interven-
tion) design to measure the chronic effects of exercise or
exercise and diet in women with PCOS. We defined ex-
ercise as a potential disruption to homeostasis by muscle
activity that is either exclusively, or in combination, con-
centric, eccentric, or isometric [27]. Accordingly, we ac-
cepted all methods of exercise training, including
continuous aerobic exercise (e.g., walking, jogging, or
cycling); high-intensity interval training; resistance train-
ing; flexibility training; and yoga, Tai Chi, and Pilates.
Trials were eligible if they had a pre-post design that
compared at least two conditions, using either
within-subject crossover design or between-subject com-
parison to a control/alternative treatment group. Studies,
which included follow-up testing at least 1 month after
completion of the intervention, were also included.
The databases searched were CENTRAL (in the
Cochrane Library), PubMed, CINAHL, SCOPUS,
EMBASE (via Web of Science), SportDiscus (via EBS-
COhost), and PsycINFO (via OvidSP). A search algo-
rithm was developed for PubMed (Additional file 1:
Table S1), which was then modified for each database
searched.
Searches were completed in June 2017 with no time
limit specified for trial inclusion. Only fully published,
peer-reviewed papers were included, whereas grey litera-
ture was not eligible. No language restrictions were
placed on the search.
Initial searches were completed by one reviewer (CK),
duplicate records were removed before title, and ab-
stracts were screened independently by two reviewers
(CK and IML). Subsequently, full-text eligibility screen-
ing was completed independently by two reviewers (CK
and IML). Any disagreements on eligibility were resolved
by discussion, whilst any unresolved disagreements by
arbitration from a third reviewer (DRB).
Where multiple publications for the same trial were
retrieved, they were linked together, and the earliest
paper of the trial was used as the primary reference. The
earliest paper was used as the reference only, and data
were extracted from all papers with the most compre-
hensive available data included for each outcome. Data
were extracted from eligible studies, and a summary of
these findings are presented in Table 2. Trial data were
combined in meta-analyses using Review Manager (Rev-
Man 5.3.5, Copenhagen, Denmark).
All trial outcomes were considered for inclusion follow-
ing the search, but the primary outcomes were those
linked to CVD risk (e.g., blood pressure, lipids, and glu-
cose). Secondary outcomes were cardiorespiratory fitness
(CRF), anthropometric measures, androgen levels,
pro-inflammatory markers, and psychosocial outcomes.Assessment of risk of bias in included studies
The Cochrane Collaboration’s tool for assessing risk of
bias was used; and six specific domains (sequence gener-
ation, allocation concealment, blinding, incomplete out-
come data, selective outcome reporting, and any other
sources of bias) were assessed. Two reviewers (CK and
IA) assessed risk of bias, and a third reviewer (IML) ar-
bitrated conflicts not due to assessor error. The
Cochrane Handbook recommendations [28] were
followed, and each bias parameter was graded as either
high, low, or unclear risk. We judged studies with > 20%
of data missing as at a high risk of attrition bias. We
considered studies with between-group baseline differ-
ences that may affect the outcome, less than 75% adher-
ence in the intervention group, and contamination in
the control group (i.e., control group participants en-
gaged in exercise), as high risk of ‘other sources of bias’
[29]. In exercise trials, it is difficult to blind participants
and researchers to the interventions resulting in a high
risk of performance bias being made; this should not
infer that the methodological quality of the trial is poor,
but rather that the inevitable bias related to lack of
blinding has been acknowledged by the reviewers. A risk
of bias table is presented in Additional file 1: Table S2
and risk of bias summarised in the results (Fig. 2; Add-
itional file 2: Figure S1).
Strategy for data synthesis
Where data from ≥ 2 trials were available, pooled inter-
vention effect estimates and their 95% confidence inter-
vals (CIs) are presented. Meta-analytical methods for
involving continuous outcomes assume that data are
normally distributed; hence, data were excluded from
the meta-analysis when they were clearly skewed, or re-
sults were reported with median and range values, and
non-parametric tests used for analysis.
Outcomes across each trial were presented as continuous
data and, based on the Cochrane Handbook’s recommenda-
tions [30], the random-effects method for meta-analysis was
utilised to combine data [31]. Mean ± standard deviation
(SD) data for either change from baseline to
post-intervention or immediately post-intervention values
were combined in a meta-analysis. The RevMan calculator
was used to convert standard errors, CIs, or t values to SD
where necessary. A priori, the analysis was based on change
from baseline scores as it removed a component of
between-person variability [30]; immediately, post-
intervention analysis was also included so as to nullify the ef-
fect of selective reporting, but also to better indicate whether
there was a treatment effect regardless of baseline values.
Mean difference (MD) was used where trials reported the
same outcome using the same scale. Where scales varied,
units of measurement were converted to the most common
measure [e.g., fasting insulin (FI) converted from pmol/L to
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ence (SMD) was used. Immediately, post-intervention values
were also assessed, and their data reported. If trials contained
more than one eligible intervention arm [32, 33], outcome
data from both groups were combined using methods rec-
ommended by Deeks et al. [30]. If an included trial used a
crossover design [34], then only data up to the point of
crossover were used.
We used the Grades of Recommendation, Assessment,
Development, and Evaluation (GRADE) approach [35]
to assess the quality of the evidence for our primary out-
comes: systolic and diastolic blood pressure, blood glu-
cose, FI, homeostatic model assessment of insulin
resistance index (HOMA-IR), total cholesterol (TC),
low-density lipoprotein cholesterol (LDL-C),
high-density lipoprotein cholesterol (HDL-C), and tri-
glycerides. GRADEpro GDT software was used to de-
velop the ‘Summary of findings’ table, and two review
authors (IML and CK) graded the quality of the evidence
for each outcome. We did not downgrade based on lack
of blinding alone due to difficulties of blinding partici-
pants and exercise supervising personnel. We down-
graded based on risk of bias only if a lack of blinding
was accompanied by additional high risks of bias (e.g.,
selection bias and incomplete outcome reporting).
Investigation of heterogeneity
The I2 statistic was used to evaluate the heterogeneity of
results for each outcome, across studies. Although not a
measure of absolute heterogeneity, the I2 describes the
percentage of variability in the point estimates that is
due to heterogeneity rather than sampling error [30].
We interpreted heterogeneity as 0–40% ‘might not be
important’, 30–60% ‘may represent moderate heterogen-
eity’, 50–90% ‘may represent substantial heterogeneity’,
and 75–90% ‘considerable heterogeneity’ [30]. The im-
portance of the observed I2 value depends on the magni-
tude and direction of effects, as well as the strength of
evidence for heterogeneity. Visual inspection of forest
plots was completed, and statistical heterogeneity as-
sumed if there was little or no overlap of CIs for the re-
sults of individual studies. When evidence of at least
substantial heterogeneity was present, its source was in-
vestigated by study population groups—the trial that
represented the largest outlier was removed from the
analysis and the I2 was re-evaluated. If heterogeneity was
not reduced, it was also assessed in subgroup analyses.
Assessment of reporting biases
To investigate publication bias, if there were ≥ 10 trials
included in an analysis, we used a funnel plot to explore
the possibility of small study effects—a tendency for
smaller studies to report larger beneficial effects. This
was only completed for one outcome (BMI) becausewhen there are fewer studies (< 10), the power of tests is
too low to distinguish chance from real asymmetry [30].
Subgroup analysis
Where there were data from ≥ 2 studies, analyses of sub-
groups was conducted. Study characteristics analysed
were body mass index (BMI) upon study entry (BMI ≤
24.9 kg/m2, 25.0–29.9 kg/m2 or ≥ 30.0 kg/m2), interven-
tion type (aerobic exercise, resistance training, or com-
bination of the two), intervention duration (≤ 12 weeks
or > 12 weeks), and intervention delivery format (super-
vised, unsupervised, or mixed delivery). Outcome data
were separated by subgroup, and subtotal summary sta-
tistics were presented. The available data were insuffi-
cient to complete three of the sub-analyses (exercise
intensity, combined treatments, and behaviour change
components) outlined in the original protocol, but find-
ings have been reported qualitatively where available.
Sensitivity analysis
Sensitivity analyses were completed on outcomes where
an effect was observed to assess the effect of removing
small sample size studies (n < 30 total participants) and
those with high overall bias risk. Due to the nature of
the interventions, performance and detection bias were
removed from the reviewers’ judgement. All studies ex-
hibited at least one domain where risk of bias was un-
clear, so only those with at least one domain where risk
of bias was deemed to be high were removed.
Results
Description of included studies
Search results
In total, 2390 articles were identified from the database
searches; we were also sent one additional article after
requesting further information from another author [36].
After removing duplicates, 1908 articles were screened for
eligibility based on title and abstract. A total of 87 full-text
articles were retrieved for detailed eligibility evaluation,
and 60 of these were excluded [37–96] with reasons de-
tailed in Fig. 1 and Additional file 1: Table S3.
Following exclusion, 27 met the inclusion criteria
[32–34, 36, 97–104, 106–119]. However, these publi-
cations were based on 18 trials, since four trials had
multiple publications, namely Stener-Victorin et al.
[111] four additional papers [101, 103, 112, 113];
Thomson et al. [33] three additional publications
[114–116]; Nybacka et al. [105] one additional publi-
cation [106]; and Sa et al. [108] one additional publi-
cation [36].
One study was excluded from the meta-analysis [97]
because data were reported as median and range values
(attempts to contact the author were unsuccessful).
Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram
Kite et al. Systematic Reviews            (2019) 8:51 Page 8 of 28Eligible studies design and attrition
Of the 18 included trials, 16 were randomised controlled
clinical trials (RCTs), whilst one trial had a quasi-RCT
[107] and another a randomised crossover [34] design.
Twelve trials compared exercise to usual care or minimal
intervention [32, 34, 97, 102, 104, 108–111, 117–119].
Three trials each compared combined exercise and diet
with diet only [33, 98, [105]], and exercise and diet com-
bined with usual care [99, 100, 107]. Only one trial [105]in-
vestigated exercise versus diet and exercise versus exercise
and diet combined. The total number of participants in-
cluded within the trials were 758 (exercise/intervention, n
= 230; control, n = 257; combined treatment arms, n = 174;
and diet alone, n = 54). In addition, 43 participants were in-
cluded in ineligible arms, i.e., pharmacological arm [100,
107, 110] and low-frequency electroacupuncture [111].
Eight trials (44%) did not report any attrition [98, 99,
102, 104, 107, 109, 110, 118]. Where reported, attrition
ranged from 6% [117] to 50% [33] with a median value
of 19.5%; five trials (28%) reported attrition over 20%
[32, 33, 97, 100, 105]. Reasons for exercise dropouts in-
cluded non-exercise related injury [32–34, 97, 119],
pregnancy [32–34, 100, 119], time [33, 34, 97], work/
family commitments [32, 33, 119], personal reasons [33,105, 108, 111], medical grounds [97, 105, 111], and re-
location [33]. Two trials excluded participants because
adherence to intervention was < 75% [117] or failure to
comply with study requirements [33].
Participant characteristics of included studies
Participant characteristics are presented in Table 2. In-
cluded trials used a range of criteria to diagnose PCOS as
presented in Additional file 1: Table S4, with three trials
[97, 99, 100] using the NIH diagnostic criteria [120],
whereas 14 [32–34, 98, 102, 104, 105, 107–111, 117, 118]
used the Rotterdam consensus criteria [121]. One trial con-
firmed the PCOS diagnosis via participants’ general practi-
tioner/specialist [119], but criteria used were unclear. No
trials specified use of the AE-PCOS definition [122].
Participants with T2DM, fasting hyperglycaemia, or
glucose intolerance were explicitly excluded in nine trials
(50%) [33, 34, 97, 98, 102, 109, 111, 117, 118], and nine
trials also excluded participants with any diagnosed
CVD [33, 34, 98, 99, 109, 111, 117–119]. Another pre-
requisite in seven trials (39%) was the activity status of
participants upon enrolment, namely a sedentary life-
style and no recent participation in an exercise interven-
tion had to be apparent [32, 33, 97, 102, 104, 109, 119].
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Fourteen trials (74%) assessed the effectiveness of an
exercise-only intervention and six trials (32%) assessed a
combined exercise and dietary intervention. Moreover,
14 trials (74%) included intervention arms consisting of
aerobic exercise only, and a further three (16%) com-
bined aerobic exercise with resistance training [33, 98,
117]. Of those incorporating aerobic exercise (n = 17,
94%), 11 trials (61%) specified either walking, brisk walk-
ing, or jogging [32–34, 97–99, 104, 105, 108, 109, 111]
and seven (39%) incorporated static cycling either on its
own or as part of a wider intervention [32, 34, 97, 98,
102, 111, 118]. A trial each incorporated elliptical train-
ing [97], step training [117] or swimming [105]. Five tri-
als (28%) [32, 97, 98, 105, 111] allowed participants to
self-select modality from those listed above, whereas two
trials [100, 107] allowed participants to self-select a mo-
dality but without stating the choices. Three trials (16%)
had arms that were resistance training only [32, 110,
119]. However, in one trial, the type of exercise was un-
clear [107].
The modal training session frequency was three per
week in 10 trials (56%) [32, 33, 98, 104, 108–111, 117,
118]. Five sessions per week were prescribed in three
(17%) trials [33, 99, 102], whereas in another trial [119]
four sessions per week were set. Of the remaining four
trials, one specified a weekly physical activity (PA) time
target of 150min per week [100], one trial set an exer-
cise dose of 14 kcal/kg/week [97], and two did not spe-
cify training frequency or volume [105, 107].
Eight trials (44%) set aerobic exercise intensity using a
percentage of the maximum heart rate (HRmax) [32–34,
98, 104, 108, 109, 117] or maximal oxygen uptake (VO2
max) [97, 102, 118]. One trial specified that heart rate
(HR) was set at ≥ 120 beats/min [111]. Three trials using
resistance training prescribed intensity based on a per-
centage of 1-repetition maximum (either 40–60% [110]
or 50–75% [32, 33]). One resistance training interven-
tion set intensity using a rate of perceived exertion of 5–
6 out of 10 [117]. Six trials did not specify the intensity
of the intervention [98–100, 105, 107, 119]. Four trials
increased the intensity as the intervention progressed
[10–104, 106–110].
Eleven trials (61%) prescribed session durations of
1 hour or less (≤ 30min [32, 34, 104, 109, 118], > 30–60
min [97, 102, 108, 111, 119], or 20–30 to 45 min [33]).
Only one trial consisted of training sessions of > 60min
[98]. Hoeger and colleagues [100] specified 150 min as a
weekly target, whereas another trial used a target dis-
tance of 10 miles per week [99]. Four trials did not spe-
cify timings for their intervention [11, 105, 107, 110].
In ten trials (56%), participants were fully supervised
in all exercise sessions [34, 98, 102, 104, 105, 108–110,
117, 118], whilst two (11%) used a mixed approach withsome supervised sessions [32, 119] and one (6%) was un-
supervised with support provided weekly by telephone
[111]. The remaining five trials (26%) did not report
supervision status.
Six trials (33%) incorporated a dietary component. Five
of these trials (28%) specified either a daily caloric target
[33, 99], a reduced caloric intake [105, 107], or an indivi-
dualised caloric deficit [100]. The other of these trials
[98] used weekly nutritional counselling sessions to edu-
cate participants on a range of nutritional topics.
Thirteen trials (72%) had a control arm (Table 2) [32,
34, 96. 98, 101, 103, 107, 109–111, 117–119]. Three of
these trials offered participants the intervention [34, 99]
or a 1-month gym membership [32] upon completion of
the trial (wait-list control). Three of the remaining trials
(17%) used a diet-only arm as their comparison group
[33, 98, 105], one trial used a placebo [100], and another
used metformin treatment only [107].
Characteristics of the outcome measures
All studies assessed participants at baseline and immedi-
ately post-intervention (Table 2), whilst two trials incor-
porated an additional midway assessment [33, 100], one
trial added a follow-up assessment 16 weeks
post-intervention [111], and another trial assessed at
baseline, crossover, and immediately post-intervention
[34]. No post-intervention follow-up analysis was pos-
sible due to lack of studies.
Seven trials (39%) stated the sample size calculation
methods [32, 97, 105, 108–111, 118], although only five
(28%) of those reported the outcome upon which their
calculations were based [32, 97, 108, 111]. The primary
outcomes (used in sample size calculation) were
HOMA-IR [32], VO2 peak [108], total testosterone
[111], insulin sensitivity [97], and BMI [105]. Only three
trials stated recruitment targets [32, 108, 111]; all three
trials achieved their sample size calculated target. The
outcomes included in each trial are provided in Table 2.
Assessment of risk of bias in included studies
The authors’ risk of bias judgements are presented in
the risk of bias graph (Fig. 2), whilst further details are
included in Additional file 2: Figure S1 and Add-
itional file 1: Table S2.
Only four trials (22%) were judged to have a low risk
of selection bias, using appropriate methods to generate
their randomisation sequence and conceal allocation [32,
97, 117, 119]. One trial was judged to be at high risk of
selection bias [108] because five participants were allo-
cated to the control group based upon their geographical
location. The remaining trials were judged to have an
unclear risk of selection bias due to insufficient report-
ing of sequence generation or allocation concealment
methods. Due to the nature of the interventions, all
Fig. 2 Review of authors’ judgement of each methodological quality item from the Cochrane Risk of Bias tool, presented as a percentage across
all 18 included studies
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bias. Only one trial had a low risk for detection bias
[118]; the remaining trials were judged to be at a high
risk of this bias due to not stating whether outcome as-
sessors were blinded to participant allocation. One trial
[32] used an independent, and blinded, assessor for
evaluation of only one outcome (flow-mediated dilation).
Eight trials (44%) were judged to be high risk for attri-
tion bias because participant withdrawal rates were > 20%
[33, 97, 100, 105, 111], incomplete data due to lab error
[98], inappropriate handling of missing data (i.e., last ob-
servation carried forward) [119], and only a subset of par-
ticipants completing hyperinsulinaemic-euglycaemic
clamp testing [102]. A prospective protocol document or
trial registration was available only for three trials, thus
making it difficult to judge whether all intended outcomes
had been reported. The remaining 14 trials (78%) were
judged to have an unclear risk of reporting bias, and one
trial [108] was judged to be high risk due to incomplete
reporting of results.
Eleven trials (61%) had low risk of bias based upon
statistical similarities between groups at baseline [32, 34,
98–100, 102, 105, 108, 111, 114, 117]. Of the high-risk
trials, one [119] had participants in the intervention
group with less favourable adiposity and body compos-
ition versus control. Similarly, another trial [97] had an
older exercise group that was less hyperandrogenic and
hirsute, and had lower levels of CRF and higher BMI,
plasma lipids, and IR levels compared with controls.
Adherence was reported in seven trials (39%) [32,
34, 97, 111, 117–119], with a median of 90% adher-
ence, ranging from 67% [34] to 103% [111]. Two of
the trials (11%) reported intervention adherence
below the 75% threshold outlined in the “Methods”
section [34, 119]. Five trials (28%) were judged to
have a low risk of adherence bias (adherence ≥ 75%)[32, 97, 111, 117, 118]. Finally, most trials (n = 14,
78%) were deemed to have unclear risk of contamin-
ation bias due to lack of reporting. Only one trial
[118] had a low risk of contamination bias as the
control group did not increase PA > 4 MET/h/week
[123], whereas three trials (17%) had a high risk of
contamination as it was reported that comparison
groups had either engaged in treatment [34, 111] or
control groups had not received their allocated inter-
vention [108].
Effects of interventions: Exercise versus control
Due to data availability, a meta-analysis was possible
only for three comparisons: (1) exercise versus control,
(2) exercise and diet combined versus control, and (3)
exercise and diet combined versus diet only.
Eleven trials were included in the exercise versus con-
trol meta-analysis as presented in Table 3 [32, 34, 102,
104, 108–111, 117–119].
Primary outcomes
Blood pressure
Four eligible trials (158 participants) assessed changes
in blood pressure. We found no significant effect of
exercise on systolic blood pressure (SBP) or diastolic
blood pressure (DBP) for either change scores or
post-intervention values compared with control (Table
3). We rated the result of both SBP and DBP as
low-quality evidence due to imprecision (small number
of participants, and a null and appreciable effect were in-
cluded in the 95% CI for the MD), and high or unclear
risk of selection bias, detection bias, reporting bias, attri-
tion bias, and contamination (see Table 4; Summary of
findings for primary outcomes).
In subgroup analyses (Additional file 1: Table S5), we
only found effects of supervised interventions (MD: −
Table 3 Effect estimates and heterogeneity for change from baseline to post-intervention scores and immediately post-intervention
values, for all outcomes analysed in the exercise versus control comparison
Outcome References Change from baseline Immediately post-intervention values
N MD Lower 95%
CI
Upper 95%
CI
I2
(%)
N MD Lower 95%
CI
Upper 95%
CI
I2
(%)
SBP (mmHg) [101, 108, 117, 118] 158 − 2.93 − 7.06 1.20 50 158 2.02 − 6.82 10.86 87
DBP (mmHg) [101, 108, 117, 118] 158 − 2.19 − 5.23 0.85 46 158 − 0.82 − 3.49 1.84 31
FBG (mg/dL) [32, 100, 101, 107, 109, 110, 117–119] 263 − 1.08 − 2.47 0.30 16 238 − 1.69 − 4.35 0.97 37
FI (μIU/mL) [32, 100, 101, 107, 109, 110, 117–119] 263 −
2.44**
− 4.24 − 0.64 91 238 −
2.11**
− 3.49 − 0.73 40
HOMA-IR [32, 100, 101, 107, 109, 110, 117, 119] 173 −
0.57**
− 0.99 − 0.14 87 148 − 0.22 − 0.80 0.36 69
TC (mg/dL) [32, 101, 108–110, 117, 118] 225 −
5.88**
− 9.92 − 1.83 35 225 −
6.35**
− 10.76 − 1.95 0
LDL-C (mg/dL) [32, 101, 108–110, 117, 118] 225 −
7.39***
− 9.83 − 4.95 0 225 −
6.68**
− 11.66 − 1.70 0
HDL-C (mg/dL)▲ [32, 101, 108–110, 117, 118] 225 0.29 − 1.46 2.04 52 225 1.87 − 1.59 5.33 65
TG (mg/dL) [32, 101, 108–110, 117, 118] 225 −
4.78***
− 7.52 − 2.05 3 225 − 1.97 − 7.36 3.42 18
VO2 max (ml/kg/min)
▲ [32, 100, 103, 107, 109, 118] 229 3.84*** 2.87 4.81 17 184 5.01*** 3.48 6.54 42
RHR (bpm) [32, 101, 117, 118] 156 − 2.65 − 5.55 0.25 51 156 −
3.26***
− 4.93 − 1.59 0
BMI (kg/m2) [32, 34, 100, 101, 103, 107, 109, 110, 117,
118, 119]
331 − 0.49 − 1.04 0.06 66 272 −
1.02**
− 1.81 − 0.23 0
Body Mass (kg) [32, 34, 101, 103, 109, 110, 119] 139 − 1.25 − 3.27 0.76 33 128 − 0.48 − 4.86 3.91 0
WC (cm) [32, 34, 108, 109, 117–119] 221 −
2.62***
− 4.13 − 1.11 53 221 − 2.33 − 5.23 0.58 15
WHR [101, 118] 101 − 0.03 − 0.08 0.02 0 101 − 0.04 − 0.08 0.01 19
Body Fat (%) [32, 109, 119] 60 − 1.39* − 2.61 − 0.18 30 60 − 3.28 − 7.39 0.83 22
Fat Mass (kg) [32, 101, 119] 63 − 1.70 − 3.93 0.53 70 38 5.14 − 14.39 24.68 65
FFM (kg)▲ [32, 101, 119] 63 0.46 − 0.89 1.81 58 38 4.99 − 7.31 17.28 75
Testosterone (nmol/L) [32, 101, 117–119] 203 − 0.09 − 0.24 0.06 0 169 − 0.08 − 0.35 0.19 37
SHBG (nmol/L) [32, 101, 118, 119] 173 7.51 − 8.01 23.04 89 139 4.03 − 18.57 26.63 66
Free T (pg/mL) [101, 117] 74 − 0.43 − 1.74 0.88 76 41 0.33 − 0.10 0.77 0
FAI [32, 101, 118, 119] 139 0.24 − 0.55 1.04 0 139 0.68 − 1.09 2.44 46
FG [101, 118] 135 − 0.63 − 2.08 0.81 0 101 − 0.75 − 2.03 0.54 0
Oestradiol (pmol/L) [100, 101, 117, 118] 190 − 13.94 − 54.53 26.64 65 120 0.27 − 11.27 11.80 0
DHEA-S (μmol/L) [32, 101] 70 − 0.60 − 1.58 0.39 0 36 − 0.20 − 1.87 1.46 0
LH (IU/L) [101, 104, 117, 118] 185 − 0.30 − 2.54 1.95 72 151 − 0.66 − 2.39 1.06 43
FSH (IU/L) [101, 104, 117, 118] 185 0.23 − 0.08 0.53 0 151 − 0.01 − 0.40 0.37 0
LH/FSH ratio [101, 117] 41 − 0.02 − 0.38 0.33 0 41 0.32 − 0.22 0.86 37
PG (nmol/L) [102, 118] 115 − 0.72 − 2.53 1.09 74 – – – – –
Prolactin (ng/mL) [104, 118] 110 − 0.05 − 0.71 0.61 0 110 0.20 − 0.27 0.68 0
hsCRP (mg/L) [32, 119] 38 − 0.41 − 1.19 0.37 0 38 0.67 − 1.31 2.65 0
AMH (ng/mL) [32, 109, 110] 67 − 0.67 − 1.65 0.32 0 67 0.48 − 1.89 2.84 0
Adiponectin (μg/mL) [32, 101] 70 − 0.20 − 1.04 0.64 0 – – – – –
Effect estimates are reported as mean differences (MD) and 95% confidence intervals, between exercise and usual care groups. Heterogeneity reported using
I2 statistic
Key: 95% CI 95% confidence intervals, SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose, FI fasting insulin, HOMA-IR
homeostatic model of assessment - insulin resistance, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol,
TG triglycerides, RHR resting heart rate, BMI body mass index, WC waist circumference, WHR waist-to-hip ratio, FFM fat-free mass, SHBG sex hormone binding
globulin, Free T free testosterone, FAI free androgen index, FG Ferriman-Gallwey score, DHEA-S dehydroepiandrosterone sulfate, LH luteinising hormone, FSH
follicle stimulating hormone, PG progesterone, hsCRP high-sensitivity C-reactive protein, AMH anti-Müllerian hormone. N number or participants included
within analysis
▲Positive values favour exercise over control.
•Study only included in the change from baseline analysis
Statistically significant effects denoted by *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001
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pants, I2 = 31%) on the SBP change compared with con-
trol. No effects were found in the subgroup analysis of
SBP post-intervention values or in any DBP subgroup
analysis.
Fasting blood glucose
Based on data from nine trials (263 participants), we
found no effect of exercise on fasting blood glucose
(FBG) change or absolute post-intervention values com-
pared with control (Table 3). There was also no effect of
exercise for any of the subgroup analyses presented in
Additional file 1: Table S5. We rated the result as
low-quality evidence due to an unclear or high-risk of
selection, detection, and reporting bias, contamination,
low adherence, small number of participants, and a null
or negligible effect and appreciable benefit included in
the confidence interval for the mean difference
(Table 4).
Fasting insulin
Meta-analysis of nine trials (263 participants) revealed a
favourable effect of exercise on the change of FI values
from baseline compared with control (MD − 2.44 μIU/
mL, 95% CI − 4.24 to − 0.64; Fig. 3), but with evidence
of considerable heterogeneity (I2 = 91%). Similarly, statis-
tically significant lowering effects of exercise versusFig. 3 Forest plot of comparison: exercise vs. control, outcome: fasting insucontrol were found for FI post-intervention values (MD
− 2.11 μIU/mL, 95% CI − 3.49 to − 0.73; 8 trials, 238 par-
ticipants, I2 = 40%). Applying GRADE, we rated the re-
sult as very low-quality (Table 4) evidence due to
unclear or high-risk randomisation or allocation proce-
dures, lack of blinding, high rate of incomplete outcome
data, unclear reporting of outcomes and contamination,
low adherence, considerable heterogeneity in the effects
in individual studies, small number of participants, and
wide confidence interval for the mean difference.
In sensitivity analyses, the observed effect of exercise
on FI change from baseline remained when only trials
with larger sample sizes (n ≥ 30 total participants) (MD
− 1.09 μIU/mL, 95% CI − 1.64 to − 0.53; 2 trials, 120 par-
ticipants, I2 = 7%) and studies with a low risk of bias
(MD − 3.18 μIU/mL, 95% CI − 5.63 to − 0.74; 187 partic-
ipants, 5 trials, I2 = 95%) were included. Likewise,
post-intervention FI effects remained when small trials
(MD − 1.73 μIU/mL, 95% CI − 3.00 to − 0.47; 2 trials,
160 participants, I2 = 5%) and trials with a high risk of
bias (MD − 2.10 μIU/mL, 95% CI − 3.04 to − 1.17; 5 tri-
als, 187 participants, I2 = 0%) were removed.
To identify the potential source of heterogeneity in the
FI change analysis, when the greatest outlier [110] was
removed, the I2 statistic was reduced to a level that may
not be important (18%) and the effect was maintained
(MD − 1.54 μIU/mL, 95% CI − 2.36 to − 0.71). Thelin plasma levels (μIU/mL)
Kite et al. Systematic Reviews            (2019) 8:51 Page 14 of 28results of the removed trial may have varied due to the
mode of exercise used (resistance training) or the use of
a placebo.
A statistical effect of exercise versus control on FI was
shown in multiple subgroups (Additional file 1: Table
S5). We found a change in FI from baseline to
post-intervention in studies with participants who were
overweight (BMI 25–29.9 kg/m2, MD − 3.25 μIU/mL,
95% CI − 5.27 to − 1.22; 5 trials, 168 participants, I2 =
75%); interventions that were aerobic exercise-based
(MD − 2.22 μIU/mL, 95% CI − 3.57 to − 0.86; 6 trials,
192 participants, I2 = 10%); ≤ 12 weeks duration (MD −
2.92 μIU/mL, 95% CI − 4.91 to − 0.93; 7 trials, 225 par-
ticipants, I2 = 93%); and supervised and combined super-
vised and unsupervised (MD − 2.54 μIU/mL, 95% CI −
4.82 to − 0.26; 6 trials, 214 participants, I2 = 94%, and
MD − 3.08 μIU/mL, 95% CI − 5.63 to − 0.53; 2 trials, 38
participants, I2 = 17%, respectively).
Compared with control, favourable effects of exercise on
FI post-intervention values were found for participants
who were overweight (MD − 2.27 μIU/mL, 95% CI − 3.24
to − 1.31; 5 trials, 168 participants, I2 = 0%); interventions
that were aerobic exercise-based (MD − 2.48 μIU/mL,
95% CI − 3.92 to − 1.04; 5 trials, 167 participants, I2 =
10%); ≤ 12 weeks duration (MD − 1.80 μIU/mL, 95% CI −
3.18 to − 0.42; 6 trials, 200 participants, I2 = 32%); and su-
pervised (MD − 2.39 μIU/mL, 95% CI − 3.62 to − 1.17; 5
trials, 189 participants, I2 = 30%).
HOMA-IR
Greater reductions in HOMA-IR change scores were evi-
dent for exercise versus control (MD − 0.57, 95% CI − 0.99
to − 0.14; 8 trials, 173 participants, I2 = 87%; Table 3; Fig. 4),
but the comparison of post-intervention HOMA-IR values
did not reveal a significant exercise effect. In a sensitivity
analysis including only trials at a low risk of bias, the effect
of exercise was maintained (MD − 0.81, 95% CI − 1.40 to −
0.21; 97 participants, 4 trials, I2 = 77%) for HOMA-IR
changes. Only one trial had a sample size of ≥ 30 partici-
pants [117], so a corresponding sensitivity analysis was not
possible. We rated the result as very low-quality evidence
due to unclear or high risk of selection, detection, attrition,
and reporting bias, contamination, low adherence, consid-
erable heterogeneity with minimal or no overlap of confi-
dence intervals, small number of participants, and a null or
negligible effect and appreciable benefit included in the
confidence interval for the mean difference (Table 4).
In the investigation of heterogeneity, removing the
most extreme value [32] had a negligible effect on the I2
(89%), but a small effect was maintained (MD − 0.50,
95% CI − 0.96 to − 0.05). Similarly, the I2 statistic was
still representative of at least substantial heterogeneity in
sub-analyses. The lowest reported value (I2 = 60%) was
in the aerobic exercise intervention subgroup.Subgroup analyses revealed statistical effects on
HOMA-IR change from baseline for aerobic exercise in-
terventions (MD − 0.73, 95% CI − 1.24 to − 0.21; 5 trials,
102 participants, I2 = 60%); ≤ 12 weeks duration (MD −
0.69, 95% CI − 1.13 to − 0.26; 6 trials, 135 participants,
I2 = 89%); and supervised delivery (MD − 0.80, 95% CI −
1.19 to − 0.42; 5 trials, 124 participants, I2 = 76%); and
for participants in the overweight subgroup (MD − 0.83,
95% CI − 1.39 to − 0.26; 4 trials, 78 participants, I2 =
75%). Post-intervention subgroup analysis revealed no
effects (Additional file 1: Table S5).
Circulating lipids
Seven trials (225 participants) were included in the ana-
lysis of all lipid-related outcomes (TC, LDL-C, and
HDL-C, and triglycerides; Fig. 5; Table 3). A statistically
significant effect of exercise versus control was observed
for TC change scores (MD − 5.88 mg/dL, 95% CI − 9.92
to − 1.83; I2 = 35%), LDL-C (MD − 7.39 mg/dL, 95% CI
− 9.83 to − 4.95; I2 = 0%), and triglycerides (MD − 4.78
mg/dL, 95% CI − 7.52 to − 2.05; I2 = 3%), but not for
HDL-C (Table 3). Post-intervention values analysis of
lipid-related outcomes revealed an effect on TC (MD −
6.35 mg/dL, 95% CI − 10.76 to − 1.95; I2 = 0%) and
LDL-C (MD − 6.68 mg/dL, 95% CI − 11.66 to − 1.70;
I2 = 0%) (Table 3). We rated these results as low-quality
evidence (Table 4) due to high or unclear risk of selec-
tion bias, detection bias, reporting bias, contamination,
and imprecision due to small number of participants
and wide confidence intervals in the included trials.
In sensitivity analyses, the favourable effects of exer-
cise versus control on TC, LDL-C, and triglycerides
change scores were maintained in studies with a low risk
of bias (MD − 5.94 md/dL, 95% CI − 10.32 to − 1.55; 5
trials, 187 participants, I2 = 40%; MD − 6.60 mg/dL, 95%
CI − 9.88 to − 3.32; 5 trials, 187 participants, I2 = 14%;
and MD − 5.97 mg/dL, 95% CI − 10.91 to − 1.03; 5 trials,
187 participants, I2 = 33%, respectively), and in larger tri-
als (MD − 3.74 mg/dL, 95% CI − 6.13 to − 1.35; 120 par-
ticipants, 2 trials, I2 = 0%; MD − 8.58, 95% CI − 11.44 to
− 5.71; 120 participants, 2 trials, I2 = 0%; and MD − 3.62
mg/dL, 95% CI − 6.22 to − 1.02; 120 participants, 2 trials,
I2 = 0%, respectively). Sensitivity analyses for LDL-C
post-intervention values showed a retained effect when
trials with a high risk of bias were excluded (MD − 8.64
mg/dL, 95% CI − 16.30 to − 0.98; 5 trials, 187 partici-
pants, I2 = 22%), but not when smaller trials were
removed.
Subgroup analyses of TC change (Additional file 1:
Table S6) revealed statistical effects for interventions that
were ≤ 12 weeks duration (MD − 5.94mg/dL, 95% CI −
10.32 to − 1.55; 5 trials, 187 participants, I2 = 37%) or su-
pervised (MD − 7.25mg/dL, 95% CI − 11.92 to − 2.58; 5
trials, 189 participants, I2 = 48%). There was also an effect
Fig. 4 Forest plot of comparison: exercise vs. control, outcome: Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Fig. 5 Forest plot of comparison: exercise vs. control, change from baseline to immediately post-intervention analysis of outcomes related to lipid
profile (mg/dL)
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Fig. 6 Forest plot of comparison: exercise vs. control, standardised mean difference; outcome: VO2 max/peak
Kite et al. Systematic Reviews            (2019) 8:51 Page 16 of 28in subgroup analysis for change from baseline (MD − 6.68
mg/dL, 95% CI − 13.00 to − 0.35; 5 trials, 167 participants,
I2 = 39%) and post-intervention TC values (MD − 6.90
mg/dL, 95% CI − 11.90 to − 1.90; 5 trials, 167 participants,
I2 = 0%) in aerobic exercise interventions. Subgroup ana-
lysis of post-intervention TC also revealed an effect when
interventions > 12 weeks (MD − 9.92mg/dL, 95% CI −
17.81 to − 2.04; 2 trials, 38 participants, I2 = 0%) or were
supervised (MD − 6.76mg/dL, 95% CI − 11.27 to − 2.26; 5
trials, 189 participants, I2 = 0%).
In subgroup analyses for LDL-C change from baseline, a
statistically favourable exercise effect was found in trials con-
sisting of interventions ≤ 12weeks duration (MD − 6.60mg/
dL, 95% CI − 9.88 to − 3.32; 5 trials, 187 participants, I2 =
13%) or supervised (MD − 6.70mg/dL, 95% CI − 10.29 to −
3.12; 5 trials, 189 participants, I2 = 23%). Subgroup analysis
for LDL-C post-intervention values revealed statistical effects
in participants with BMI of 25–29.9 kg/m2 (MD − 9.54mg/
dL, 95% CI − 18.71 to − 0.36; 5 trials, 168 participants, I2 =
22%), and interventions of ≤ 12weeks duration (MD − 8.64
mg/dL, 95% CI − 16.30 to − 0.98; 5 trials, 187 participants,
I2 = 22%), supervised (MD − 7.58mg/dL, 95% CI − 13.73 to
− 1.43; 5 trials, 187 participants, I2 = 24%), or aerobic (MD:
− 5.87mg/dL, 95% CI − 11.68 to − 0.07; 5 trials, 167 partici-
pants, I2 = 0%; Additional file 1: Table S6).
For HDL-C, only subgroup analyses of resistance
training interventions showed a negative effect onchange from baseline scores (MD − 2.19 mg/dL, 95% CI
− 4.21 to − 0.18; 2 trials, 37 participants, I2 = 0%) and a
positive effect on post-intervention values (MD 7.29 mg/
dL, 95% CI 1.11 to 13.46; 2 trials, 37 participants, I2 =
17%; Additional file 1: Table S6). No effects of exercise
were found in other HDL-C subgroup analyses.
Compared with control, exercise had a favourable ef-
fect on triglyceride values in the following subgroups:
BMI 25–29.9 kg/m2 (MD − 8.17 mg/dL, 95% CI − 14.44
to − 1.89; 5 trials, 167 participants, I2 = 13%); aerobic ex-
ercise interventions (MD − 6.80 mg/dL, 95% CI − 13.12
to − 0.48; 5 trials, 167 participants, I2 = 5%); ≤ 12 weeks
duration (MD − 6.06 mg/dL, 95% CI − 10.82 to − 1.31; 5
trials, 187 participants, I2 = 30%); and supervised inter-
ventions (MD − 5.91 mg/dL, 95% CI − 10.75 to − 1.06; 5
trials, 189 participants, I2 = 29%; Additional file 1: Table
S6). Analysis of triglyceride post-intervention values re-
vealed an effect of exercise in trials > 12 weeks only (MD
− 13.85 mg/dL, 95% CI − 26.33 to − 1.36; 2 trials, 38 par-
ticipants, I2 = 0%).
Secondary outcomes
Maximal or peak oxygen uptake
A large statistical effect of exercise versus control was
found for both change from baseline and post-intervention
VO2 max/peak values (SMD 1.43, 95% CI 0.84 to 2.03; 259
participants, 7 trials, I2 = 74%, and SMD 1.19, 95% CI 0.40
Kite et al. Systematic Reviews            (2019) 8:51 Page 17 of 28to 1.99; I2 = 83%, respectively; Fig. 6). With the inclusion of
only studies that reported relative VO2 max/peak values
(i.e., expressed as ml/kg/min), the effect of exercise was
maintained in both change scores and post-intervention
values (MD 3.84ml/kg/min, 95% CI 2.87 to 4.81; 6 trials,
229 participants, I2 = 17%, and MD 5.01ml/kg/min, 95% CI
3.48 to 6.54; 5 trials, 184 participants, I2 = 42%,
respectively).
For the SMD VO2 max/peak change sensitivity analysis,
an effect remained when small trials (SMD 1.21, 95% CI 0.29
to 2.12; 3 trials, 165 participants, I2 = 83%) and those with a
high risk of bias (SMD 1.63, 95% CI 0.78 to 2.48; 5 trials, 187
participants, I2 = 80%) were removed. SMD was also used to
complete post-intervention sensitivity analysis for sample
size; 2 trials (120 participants) [116, 117] were included, but
the effect was lost. However, it remained when trials with a
high risk of bias were removed (SMD 1.16, 95% CI 0.21 to
2.12; 5 trials, 187 participants, I2 = 87%).
When we considered only relative VO2 max/peak
change scores, the effect of exercise was maintained
when removing small studies (MD 1.21 ml/kg/min, 95%
CI 0.29 to 2.12, 165 participants, 3 trials, I2 = 83%) and
studies with a high risk of bias (MD 3.35 ml/kg/min,
95% CI 2.59 to 4.10; 157 participants, 4 trials, I2 = 0%).
All trials in the post-intervention relative VO2 max/peak
analysis were considered low risk of bias, so this sensi-
tivity analysis was not possible.
For ease of interpretation, we performed subgroup ana-
lyses on the relative VO2 max/peak data. Subgroup ana-
lysis of the change from baseline relative VO2 max/peak
values revealed statistical improvements with aerobic ex-
ercise, any intervention duration, and for participants with
a BMI of 25–29.9 kg/m2. The post-intervention pooled
analysis showed an effect of exercise on relative VO2 max/
peak in four subgroups: participants with a BMI of 25–
29.9 kg/m2, aerobic exercise interventions, ≤ 12 weeks,
and supervised (Additional file 1: Table S7).
In one trial reporting data from a post-intervention
16-week follow-up [111], a 12% increase in VO2 max
(4.11 ± 5.20 ml/kg/min; p = .001) from baseline was still
evident in the exercise group. The corresponding change
for control (7%) was not statistically significant, and
there were no significant differences between groups.
Resting heart rate
A pooled analysis of four trials (156 participants) indi-
cated no effect of exercise on the change scores of rest-
ing heart rate (RHR) values (Table 3). However, in these
trials, RHR post-intervention values were statistically
lower in the exercise interventions versus control (MD
− 3.26 beats/min, 95% CI − 4.93 to − 1.59; I2 = 0%).
When post-intervention sensitivity analyses were com-
pleted, this effect was still evident in larger trials (MD −
3.18 beats/min, 95% CI − 5.59 to − 0.77, 3 trials, 145participants, I2 = 16%) and those with a low risk of bias
(MD − 3.53 beats/min, 95% CI − 5.28 to − 1.78; 2 trials,
120 participants, I2 = 0%).
In subgroup analyses, there were statistical effects of
exercise compared with control on both RHR change
from baseline and post-intervention values in interven-
tions that were aerobic exercise-based (Additional file 2:
Figure S3), and those that were supervised.
Post-intervention subgroup analysis also revealed effects
in interventions of ≤ 12 weeks and when participants
had a BMI 25–29.9 kg/m2 at study entry (Additional file 1:
Table S7).
Body mass and body mass index
We found a statistical effect of exercise on BMI
post-intervention values (MD − 1.02 kg/m2, 95% CI −
1.81 to − 0.23; 10 trials, 272 participants, I2 = 0%) com-
pared with control (Table 3). When trials with a high
risk of bias were removed from the sensitivity analysis
for BMI post-intervention values, an effect remained
(MD − 0.95 kg/m2, 95% CI − 1.78 to − 0.12; 6 trials, 207
participants, I2 = 0%), but not when small trials were
removed.
Subgroup analysis revealed a statistical reduction in
BMI change scores with exercise in studies consisting of
participants with BMI ≥ 30 kg/m2. Analysis of BMI
change from baseline also revealed a statistical decrease
with aerobic exercise interventions, but a statistical in-
crease with resistance training interventions (Add-
itional file 1: Table S7).
Post-intervention subgroup analysis revealed statistical
reductions in BMI with interventions that were aerobic
exercise-based, supervised, and ≤ 12 weeks, and also in
participants with a BMI of 25–29.9 kg/m2 (Add-
itional file 1: Table S7).
The meta-analysis revealed no effect of exercise versus
control on body mass change from baseline or
post-intervention values (Table 3). However, we found
statistical effects of exercise versus control on change in
body mass from baseline to post-intervention for studies
involving participants with BMI ≥ 30 kg/m2. No other
subgroup analyses indicated such an effect (Add-
itional file 1: Table S7).
Follow-up reporting (16-weeks post-intervention) of
BMI from one trial [111] showed no statistically signifi-
cant within-group changes or between-group differences
in either exercise or control arms. The authors [111] also
reported similar findings immediately post-intervention.
Waist and hip circumference and waist-to-hip ratio
Analysis of waist circumference (WC) change scores,
but not post-intervention values, revealed a statistically
significant beneficial effect of exercise compared with
controls (MD − 2.62 cm, 95% CI − 4.13 to − 1.11; 7 trials,
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fect of exercise on WC change remained when trials
with a low risk of bias (MD − 1.51 cm, 95% CI − 2.26 to
− 0.76; 167 participants, 4 trials, I2 = 0%) and larger sam-
ple sizes (MD − 1.48 cm, 95% CI − 2.26 to − 0.71; 120
participants, 2 trials, I2 = 0%) were analysed separately.
When the largest outlier [108] was removed from this
analysis, the I2 was reduced to 0% and an effect
remained (MD − 1.68 cm, 95% CI − 2.38 to − 0.99).
In subgroup analyses for WC change, exercise had a
statistical effect in studies with participants with BMI of
25–29.9 kg/m2 and ≥ 30 kg/m2, ≤ 12 week’s duration, aer-
obic and resistance-based interventions, and supervised
exercise (Additional file 1: Table S7). Subgroup analysis
revealed that post-intervention WC values were statisti-
cally lower in exercise interventions with participants
with BMI 25–29.9 kg/m2, aerobic exercise, and super-
vised exercise (Additional file 1: Table S7).
Data from two trials [111, 118] were pooled in the
analysis of waist-to-hip ratio (WHR); there was no effect
in either change from baseline or post-intervention
values analyses.
Body composition
The pooled MD for body fat percentage change from
baseline was statistically significant (MD − 1.39%, 95%
CI − 2.61 to − 0.18; 3 trials, 60 participants, I2 = 30%),
but not for post-intervention values (Table 3). When tri-
als deemed to have a high risk of bias were removed, this
statistical effect disappeared. Sensitivity analysis by study
size could not be performed for the exercise effect on
body fat percentage due to a lack of sufficiently large
studies. Moreover, we found no effect of exercise versus
control on change from baseline or post-intervention
analyses for fat mass and fat-free mass (Table 3).
A statistical effect was found for exercise on body fat
percentage change in interventions ≤ 12 weeks, but this
analysis included the same trials as the main analysis.
No other statistical effects were found across any of the
other subgroup analyses on body fat percentage change
(Additional file 1: Table S7). However, body fat percent-
age was statistically lower post-intervention in exercise
interventions that included participants with BMI of 25–
29.9 kg/m2, and aerobic exercise (Additional file 1: Table
S7). No effect was evident in the subgroup analysis for
fat mass or fat-free mass.
Androgenic, hormonal, and inflammatory markers
In pooled analyses of change from baseline or
post-intervention values, exercise had no beneficial effect
on any of the androgenic/hormonal and inflammatory
biomarkers/variables [i.e., testosterone, free testosterone,
free androgen index (FAI), sex hormone binding globulin
(SHBG), Ferriman-Gallwey scores, oestradiol, luteinisinghormone (LH), follicle stimulating hormone (FSH), LH/
FSH ratio, progesterone, prolactin, high-sensitivity
C-reactive protein, anti-Mullerian hormone (AMH), or
adiponectin] when compared with control (Table 3). Simi-
larly, there were no effects in any subgroup analysis for
these outcomes (Additional file 1: Table S8).
Psychosocial outcomes
In two trials (57 participants) that assessed psychosocial
outcomes using the PCOS-Q, we found no effect of exer-
cise on any PCOS-Q domain compared with control.
Three trials (84 participants) used the SF-36. Data only
allowed for change from baseline analysis and no
sub-analysis was possible. For SF-36 domains, a favourable
effect of exercise versus control was found for physical
functioning (MD 11.81, 95% CI 2.36 to 21.25; I2 = 74%),
general health (MD 10.05, 95% CI 3.89 to 16.20; I2 = 0%),
social functioning (MD 11.75, 95% CI 2.56 to 20.95; I2 =
6%), and mental health (MD 11.70, 95% CI 1.27 to 22.13;
I2 = 47%) domains (Additional file 2: Figure S5).
There were insufficient data to complete sensitivity
analyses; however, all three trials [108, 111, 119] were
judged to have a high risk of bias in at least one domain,
and only one trial had a sample size ≥ 30. Heterogeneity
was investigated in the physical functioning domain; the
largest outlier was removed [108] and the I2 was reduced
to 33%, whilst an effect was maintained (MD 7.23, 95%
CI 1.66 to 12.80). The same trial was removed in the
general health analysis, resulting in a reduction in I2 to
0%, and a preserved effect (MD 7.97, 95% CI 1.07 to
4.88). When the greatest outliers were removed from the
social functioning [119] and mental health [111] do-
mains, both I2 values were reduced to 0%, but the effect
only remained in the mental health domain (MD 17.84,
95% CI 7.33 to 28.36).
Additional outcomes
Six trials [32, 108, 111, 117–119] also reported a range
of additional outcomes; the key findings from these are
presented in Additional file 1: Table S9.
Effects of interventions: Exercise and diet versus control
Three trials compared exercise and diet combined versus
control. Only one of these trials used a control group
that was described as no treatment [99]. The other two
[100, 107] compared exercise, diet and metformin (or
placebo) to metformin only groups. As pharmacological
intervention was present in each included treatment
arm, we assumed that any variation between groups
would result from exercise and dietary components.
Due to insufficient data, it was only possible to include
two outcomes in the meta-analysis. Meta-analysis of the
two trials (68 participants) reporting change from base-
line to post-intervention WHR values revealed a small
Kite et al. Systematic Reviews            (2019) 8:51 Page 19 of 28but statistically significant effect in favour of exercise
and diet (MD − 0.02, 95% CI − 0.03 to − 0.01; I2 = 0%;
Additional file 2: Figure S6). The effect was not repli-
cated in the post-intervention value analysis.
We found no effect of exercise and diet combined ver-
sus control on the change from baseline to post-
intervention SHBG concentrations (Additional file 2:
Figure S7). There were insufficient data to complete ana-
lysis of post-intervention values or subgroups. Individual
outcomes were also reported by each of these trials,
which are summarised in Additional file 1: Table S10.
Effects of interventions: Exercise and diet versus diet
Three trials had intervention arms that compared the
combination of exercise and diet to diet only [33, 98, 104].
Analyses of change from baseline and post-intervention
values from these trials revealed no statistical difference
between combined exercise and diet or diet only interven-
tions for any assessed primary outcome (FBG, FI, andTable 5 Summary of findings for primary outcomes: exercise and di
Exercise and diet compared to Diet for women with PCOS
Patient or population: women with PCOS
Setting:
Intervention: exercise and diet
Comparison: Diet
Outcomes Anticipated absolute effects* (95% CI)
Risk with Diet Risk with exercise and die
Fasting blood glucose
(change from baseline)
follow-up: range 16
weeks to 20 weeks
The mean fasting blood
glucose (change from
baseline) ranged from
− 7.0 to − 3.2 mg/dL
The mean fasting blood g
(change from baseline) in
intervention group was 2.
higher (0.4 lower to 6.23 h
Fasting insulin (change
from baseline) follow-
up: range 12 weeks to
20 weeks
The mean fasting
insulin (change from
baseline) ranged from
− 2.9 to − 18.54 μU/ml
The mean fasting insulin (
from baseline) in the inter
group was 2.22 μU/ml hig
lower to 8.14 higher)
HOMA-IR (change from
baseline) follow-up:
range 16 weeks to 20
weeks
The mean HOMA-IR
(change from baseline)
ranged from − 0.74 to
− 0.56
The mean HOMA-IR (chan
baseline) in the interventi
was 0.01 lower (0.45 lowe
higher)
*The risk in the intervention group (and its 95% confidence interval) is based
the intervention (and its 95% CI). CI: Confidence interval; MD: Mean differenc
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of
Moderate certainty: We are moderately confident in the effect estimate: The
a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effec
Very low certainty: We have very little confidence in the effect estimate: The
effect
Explanations
aAll trials were at an unclear risk of selection bias, reporting bias, contamination, an
bias. Therefore, we downgraded by one level
bSmall number of participants, only two trials, and wide confidence intervals in the
cSubstantial heterogeneity was observed. Therefore, we downgraded by one level
dSmall number of participants and trials, wide confidence intervals, and null/negligi
mean difference. Therefore, we downgraded by two levelsHOMA-IR; all very low-quality evidence; Table 5) or sec-
ondary outcome (body weight, BMI, WC, body fat,
fat-free mass, testosterone, SHBG, and FAI; Add-
itional file 1: Table S11). There were insufficient data to
complete subgroup analyses within this comparison.
All three trials reported a range of other outcomes not
included in this meta-analysis; these are summarised in
Additional file 1: Table S12.
Effects of interventions: Exercise vs diet, and exercise and
diet vs exercise
Only one trial [105] compared exercise with diet, and exer-
cise combined with diet versus exercise only. Effects in the
diet only and combined diet and exercise group have been
reported above and in Additional file 1: Table S12. The
exercise-only intervention reduced BMI (− 0.85 kg/m2, 95%
CI − 1.69 to − 0.02; P < .05), but these changes were smaller
than those seen in the other treatment arms. Upper body
fat was statistically reduced only in the exercise group (−et versus diet
Relative
effect
(95% CI)
№ of
participants
(studies)
Certainty
of the
evidence
(GRADE)
Comments
t
lucose
the
92 mg/dL
igher)
– 78 (2 RCTs) ⨁◯◯◯
VERY
LOW a,b
We are uncertain about
the effect of exercise and
diet on fasting blood
glucose (change from
baseline).
change
vention
her (3.7
– 90 (3 RCTs) ⨁◯◯◯
VERY
LOW a,c,d
We are uncertain about
the effect of exercise and
diet on fasting insulin
(change from baseline).
ge from
on group
r to 0.43
– 78 (2 RCTs) ⨁◯◯◯
VERY
LOW a,b
We are uncertain about
the effect of exercise and
diet on HOMA-IR (change
from baseline).
on the assumed risk in the comparison group and the relative effect of
e
the estimate of the effect
true effect is likely to be close to the estimate of the effect, but there is
t may be substantially different from the estimate of the effect
true effect is likely to be substantially different from the estimate of
d adherence issues. All trials were at a high risk of detection bias and attrition
included trials. Therefore, we downgraded by two levels
ble effect and appreciable benefit included in the confidence interval for the
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number exhibited the greatest improvement in the
exercise-only group (P < .01). No within-group effects were
reported for body fat (%), lower body fat (kg), lean body
mass, free testosterone, insulin-like growth factor-1,
insulin-like growth factor binding protein-1, FBG, FI,
HOMA-IR, LH, FSH, testosterone, SHBG, T/SHBG ratio,
AMH, or mean ovarian volume.
Discussion
Summary of the main results
Our systematic review provides up-to-date evidence sup-
porting the incorporation of exercise interventions in
the management of PCOS. When exercise was compared
with control, we noted statistically beneficial changes
from baseline to post-intervention and more favourable
post-intervention values for FI, TC, LDL-C, and VO2
max. Statistically positive change from baseline scores
was also observed for HOMA-IR, triglycerides, WC, and
body fat percentage, whereas, statistically lower
post-intervention values were additionally found for
BMI and RHR. In an analysis of a limited number of
studies, compared with control, a small statistical effect
in favour of exercise and diet was evident for WHR, but
not for SHBG. In the exercise and diet versus diet only
comparison, we found no evidence of effect in any out-
come; however, there were strikingly scant data available
(Additional files 3 and Additional file 4).
Primary outcomes
We found a small change in SBP from baseline to
post-intervention with supervised exercise versus con-
trol. To our knowledge, this is the first systematic review
to report on the effects of exercise on blood pressure in
women with PCOS. Existing evidence from the general
population suggests that aerobic exercise interventions
induce the greatest improvements to SBP and DBP in
hypertensive participants [124], with less marked effects
in normotensive participants (small decreases in DBP
and no effect on SBP). The mean SBP (116mmHg) and
DBP (73 mmHg) values in our review indicates that most
PCOS participants were normotensive at baseline; thus,
a large effect was not anticipated.
Regarding surrogate markers of IR, we found a statisti-
cally beneficial change (FI and HOMA-IR) and more
favourable post-intervention values (FI) with exercise
compared with control. Subgroup analyses also indicate
that the greatest improvements are noted in participants
who were overweight or obese and from shorter dur-
ation, supervised aerobic-based interventions. These
findings agree with those of two previous systematic re-
views, which however, did not make the distinction be-
tween exercise, diet or their combination, but instead
compared lifestyle interventions to control [125, 126].The more recent of these reviews [125] reported a small,
but statistically significant effect on FI change (MD −
2.1 μIU/mL, 95% CI − 3.3 to − 1.0; 5 trials, I2 = 0%). The
other review [126] also compared the effect of lifestyle
to a minimal treatment intervention on FI showing a
statistical effect on FI post-intervention values favouring
lifestyle (MD − 2.02 μIU/mL, 95% CI − 3.28 to − 0.77;
144 participants, 5 trials, I2 = 0%). Herein, we expanded
on these previous findings by incorporating a greater
number of trials and by separating exercise-only trials,
thus revealing that based on the available data the exer-
cise alone effects are comparable to that of lifestyle
interventions.
Although the PCOS diagnostic criteria do not cur-
rently include IR, it is widely acknowledged that IR plays
a key role in the pathophysiology of PCOS [127]. Ap-
proximately 50–70% of women with PCOS have IR and
hyperinsulinaemia [128], whereas many also present evi-
dence of glucose intolerance [20]. Hyperinsulinaemia in
PCOS further promotes secretion of androgens from the
ovarian theca cells, whilst supressing SHBG hepatic se-
cretion, thus increasing free androgens and exacerbating
the associated symptoms [129]. Despite the integral role
of IR in PCOS, there are scant FI reference values in the
literature [130]. One study [131] reported FI levels ran-
ging from 2 to 60 μIU/mL in healthy women (n = 111),
with a mean value of 17.6 ± 5.7 μIU/mL in women aged
25–34 years (n = 22). A large-scale case-control study of
women with PCOS (n = 1404) reported mean FI levels of
14.3 ± 1.6 μIU/mL, which was significantly higher than
healthy controls [132]. The mean baseline FI level of
intervention participants in our review was 16.21 μIU/
mL, and a reduction of ~ 13% was reported following ex-
ercise. Due to the variability of normative FI values in
PCOS, it is unclear whether these exercise-induced re-
ductions are clinically meaningful.
Although FI correlates with IR, several studies, espe-
cially in normoglycaemic populations [133, 134], have
shown that HOMA-IR (calculated based on FI and FBG
values) may be a better estimate of insulin sensitivity
[135]. In the present review, the mean baseline
HOMA-IR for the intervention group participants was
2.99, which dropped to 2.43 (MD − 0.57) following exer-
cise, with no evidence of reduction in the control
groups. A generally adopted HOMA-IR cut-off value for
the identification of IR is 2.6 [136]. This suggests that
exercise may have a clinically significant effect on IR
compared with usual care. Furthermore, we found no ef-
fect of exercise on FBG. Participants were within normal
FBG at baseline; thus, this combined with the effect on
FI indicates that less insulin is needed to maintain
normoglycaemia following exercise.
In contrast to previous reviews [126, 137], we report
an effect of exercise on lipid profiles. Compared to
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changes for TC, LDL-C, and triglycerides. Based on data
included in our review, the mean baseline values for TC
(233 mg/dL) and LDL-C (142 mg/dL) would be classified
as borderline high or even elevated in the presence of
concomitant CVD risk factors [138]. Post-intervention
values for LDL-C were lower for exercise compared to
control, but TC levels were comparable (approximately
229 mg/dL in both). LDL-C appears to play a pivotal role
in atherogenesis, with progressively increasing risk of
coronary heart disease (CHD) with increasing LDL
plasma levels [139]. Conversely, inverse associations be-
tween HDL-C and both atherosclerosis severity and
CHD risk have been reported, with HDL-C levels ≥ 60
mg/dL potentially protecting against CHD [140]. HDL-C
baseline and post-intervention values within this system-
atic review were > 60mg/dL, which may partially explain
why no effect of exercise was found. However, where TC
and LDL-C are elevated at baseline, a statistical effect is
evident following exercise but the magnitude of the
changes may not be clinically important [141, 142].
Mean baseline triglyceride concentrations were higher
in the exercise group (+ 11mg/dL) compared with con-
trol, but both groups were within the normal range (<
150 mg/dL). Exercise reduced triglyceride levels, but
post-intervention analysis revealed that concentrations
were still lower in the control groups. Triglycerides are
independent predictors of CVD mortality in women
[143]; however, the magnitude of the observed
exercise-induced triglyceride reduction, within the re-
ported range, is likely to have little clinical relevance. Fu-
ture research is required to investigate the independent
effect of exercise in women with hypertriglyceridaemia.
Secondary outcomes
We found a statistically and clinically significant effect
for VO2 max (> 3.5 ml/kg/min) with exercise compared
with control. Subgroup analyses revealed that aerobic
exercise, regardless of other variables, improved VO2
max in women with PCOS.
Low CRF, as measured by VO2 max, has been associ-
ated with increased risk of chronic disease and all-cause
mortality [144, 145]. Reduction in VO2 max occurs
physiologically with age, but is also often linked to in-
activity. The consequences of reduced CRF include im-
paired capability to exercise, reduced ability to perform
activities of daily living, and a lower overall quality of life
[146]. Consequently, improving patient VO2 max is a
goal of many lifestyle interventions yet is often over-
looked in PCOS. Studies assessing VO2 max in this pa-
tient population are limited; two such studies in
overweight [147] and lean [148] women with PCOS re-
veal markedly lower CRF than healthy controls. The only
previous relevant systematic review to report on VO2max/peak [137] found improvements for both lifestyle
(i.e., exercise and diet combined; MD 5.09 ml/kg/min,
95% CI 3.13 to 7.05, 3 trials, 137 participants) and exer-
cise (MD 4.86 ml/kg/min, 95% CI 2.83 to 6.88, 2 trials,
125 participants) interventions compared with usual
care. Our analysis of relative VO2 max change pooled
data from 92 more participants than the review by Haqq
et al. [137], and although our effect was marginally
smaller, the agreement between these results suggests
that exercise can improve CRF in this population.
We also found reductions in WC and body fat in the
exercise groups, suggesting that exercise promotes
favourable changes to body composition in women with
PCOS. As a measure of central/abdominal obesity, WC
is considered a better independent predictor of
obesity-related disorders than BMI [149]. This may be
attributed to the key role of central adiposity in the de-
velopment of IR and T2DM, even in those with normal
BMI [150]. However, despite statistical significance, the
exercise-induced WC changes may be of unclear clinical
relevance, since the observed average reduction from
baseline was 2.8% (95% CI 1.31 to 4.24), which is less
than the suggested 3–5% reduction considered as clinic-
ally significant [151].
Improvements in anthropometric outcomes were re-
ported by an older systematic review [137], but these
were largely based on comparing lifestyle (not exercise
alone) with control. Similarly, when compared to con-
trol, Moran et al. [126] reported statistical reductions in
body weight and abdominal adiposity following lifestyle
interventions. In our systematic review, when combined
exercise and dietary interventions were compared with
diet only, both groups demonstrated favourable changes,
but there was no evidence of an effect favouring either
intervention for any outcome.
We found no statistical effect of exercise on the andro-
genic profile of women with PCOS compared with con-
trol. Where analyses were possible, we found no effect
favouring either diet and exercise combined or diet only.
This was further supported by subgroup analyses where
the evidence of relevant effects was minimal. Typically,
the baseline values of women with PCOS included in
this current review were below recommended cut-offs
for diagnosing hyperandrogenism; testosterone > 2.5
nmol/L and SHBG < 30 nmol/L [152], which indicates
that they were not markedly hyperandrogenic. Moran
et al. [126] reported reduced testosterone levels follow-
ing lifestyle intervention but found no effect on FAI (100
× total testosterone/SHBG), a more valid marker of
hyperandrogenism [121]. A review of exercise-induced
changes on the androgenic profile of healthy women
who were premenopausal [153] found that exercise
acutely increases circulating androgens, but the chronic
effects are less clear. A similar meta-analysis [154]
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of bioavailable testosterone (MD − 0.18 pg/mL, 95% CI
− 0.29 to − 0.07; 1369 participants, 9 trials, I2 = 0%) and
increased SHBG (MD 3.93 nmol/L, 95% CI 0.98 to 6.87;
1643 participants, 14 trials, I2 = 75%) following exercise
in healthy women. Collectively, these data suggest that
exercise interventions may regulate androgenic profiles,
but that the optimal dose is unclear, with potential vari-
ation in women with menstrual disruption [155].
Finally, there is increasing recognition of the deleteri-
ous effects of PCOS on HRQoL and other psychosocial
components. However, only three eligible trials mea-
sured these outcomes in the exercise versus control
comparison. There was no evidence of effect in any of
the PCOS-Q domains, but scores were improved in the
physical functioning, general health, social functioning,
and mental health domains of the SF-36. Our
meta-analysis revealed improvements in these outcomes
of ≥ 10% for exercise compared with control, supporting
the notion that exercise in these patients may improve
their perception of physical and mental wellbeing.Overall completeness and applicability of evidence
We completed a comprehensive and systematic search
of relevant electronic databases and the reference lists
from included publications and relevant reviews. From
this, we identified 16 RCTs, one quasi-RCT, and a ran-
domised crossover trial. We located and meta-analysed
data from more trials, made a greater number of com-
parisons, and included a wider range of outcomes when
compared to previous systematic reviews [25, 125, 126,
148]. To our knowledge, it is the first time data from 10
of the trials included in this systematic review have been
meta-analysed [32, 34, 102, 104, 108–110, 117, 119] sug-
gesting that this is the most comprehensive and
up-to-date systematic review on the topic of exercise in
the treatment of women with PCOS. We followed the
PRISMA statement [26] and used the PRISMA checklist
(Additional file 3) to ensure methodological quality. Fur-
thermore, we present our entire data set for transpar-
ency and reproducibility in Additional file 4.
However, there are limitations to this systematic re-
view. It is likely that many of the included trials were
not sufficiently powered to detect meaningful differences
between test groups. Indeed, only seven included trials
state the methods used to calculate sample size, and due
to small participant numbers (e.g., median: exercise n =
11; control n = 12), it is unlikely that sufficient statistical
power was achieved to either make the findings general-
isable into the population or ensure that false positive/
negative results were not reported. Therefore, it is im-
portant that future trials are sufficiently powered to de-
tect changes in their primary outcomes.PCOS is a heterogeneous condition and can exhibit
phenotypes with varying levels of underlying hyperan-
drogenism, menstrual disorders, and polycystic ovarian
morphology [156]. It is likely that different phenotypes
may respond differently to exercise and/or dietary inter-
ventions. Most included trials did not target a specific
PCOS phenotype, and our protocol included a PCOS
diagnosis based on any of the existing PCOS definitions/
criteria. Future work should focus on PCOS subgroups/
phenotypes and investigate the exercise-induced effects
accordingly. Another concern surrounds the representa-
tiveness of the populations included in the review; it is
not clear whether the ethnicity, socio-economic, or edu-
cational status of participants is representative of the
typical patient or to what degree these variables may
have influenced the observed effects.
All included trials reported baseline and immediately
post-intervention data; only one trial [111] completed
follow-up beyond the end of the intervention. Conse-
quently, the lasting, long-term effect of exercise for
women with PCOS is unknown. Future research is
needed to determine whether behaviours relating to PA
are changed in this patient population due to exercise
interventions and whether the noted physiological ef-
fects remain beyond the short term.
Quality of the evidence
Due to the nature of the interventions, all included trials
were judged to have a high risk of performance bias. All
but one trial was judged to have a high detection bias
risk due to lack of blinding outcome assessors, and al-
though logistically difficult, steps could have been taken
to minimise this bias in each trial. Selection and report-
ing bias were inadequately reported in > 50% of trials so
a judgement of unclear risk was made and nearly 45% of
the included trials (n = 8) were judged to be at a high
risk of attrition bias. Six trials were at an unclear or high
risk of baseline group imbalance, whereas adherence and
contamination were generally unreported resulting in an
unclear judgement. Disappointingly, few studies reported
adherence data (33%, n = 6), but of the trials that did re-
port these data, adherence rates were generally good
(median 90%). Similarly, in the 10 trials reporting attri-
tion, the median value was 19.5%; five of these were
under the 20% attrition threshold outlined in the
protocol.
Statistical effects were reported in 13 of the main ana-
lyses; in three of those, there was evidence of at least
substantial heterogeneity (I2 ≥ 50%), but this was largely
explained by subgroups and/or removal of trials with the
most extreme values. For our primary outcomes, the
quality of evidence was rated as very low to low due to a
combination of unclear or high-risk randomisation or al-
location procedures, lack of blinding, unclear or
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clear risk of selective reporting bias, contamination, low
adherence, or considerable heterogeneity. We down-
graded all outcomes because of imprecision resulting
from the small number of participants and either wide
confidence intervals for the effect estimate or the null ef-
fect, as well as an appreciable benefit was included in
the confidence interval for the mean difference.
Limitations and potential biases in the review process
In addition to the limitations mentioned in “Secondary
outcomes” section, there are also further possible limita-
tions to this systematic review. Despite a thorough and
comprehensive search of relevant databases, we may
have missed trials that would have been eligible for in-
clusion. Additionally, we did not identify any additional
studies from the reference lists of the included publica-
tions; although this may support the comprehensiveness
of our searches, it may also represent a methodological
error. Also, no language restriction in our searches
meant several foreign language papers were returned;
three trials in Persian [104, 109, 110] and one in Hun-
garian [107]. To assess these trials, translation services
and software were required, and whilst interpretation of
results tables was straightforward, evaluation of meth-
odological quality was more challenging. Consequently,
when assessing risk of bias in these trials, judgements of
‘unclear risk’ had to be made.
Finally, only full publications were eligible for inclusion
and this could contribute to publication bias. Although in-
cluding grey literature may have influenced the findings of
this review, it may have also increased the risk of associ-
ated bias. Unfortunately, due to a lack of eligible trials,
publication bias analysis was not performed.
Future directions
Based upon our findings, it is apparent that there is a
lack of trials that compare exercise and diet combined
with other comparators, such as diet only, exercise only,
or a standard treatment control. Considering that life-
style changes (i.e., diet and exercise) are recommended
in the management of PCOS, studies assessing the ef-
fectiveness of these interventions are scarce and the
available data are not sufficient to lead to definite con-
clusions/recommendations for the clinical practice. Fu-
ture trials should aim to make comprehensive
comparisons involving interventions that incorporate
both exercise and diet.
Furthermore, the eligible studies included in the
current systematic review generally have small sample
sizes, whilst even those studies that have reported power
calculations appear under-powered to detect meaningful
changes in all reported outcomes. Therefore, it is im-
portant that future studies are robustly designed andsufficiently powered to better inform future clinical
practice guidelines/recommendations. Considering the
high prevalence of PCOS in reproductive-aged women,
large RCTs studying the effectiveness of lifestyle inter-
ventions in this young patient population are still clearly
needed.
We also identified a lack of follow-up testing beyond the
intervention period to assess the longer-term effects of such
lifestyle interventions. Without follow-up reassessments, it is
impossible to determine whether any intervention-induced
improvements are maintained, and if the applied interven-
tion has resulted in sustained changes in lifestyle behaviours
of participants, an aspect which is vital for the long-term
management of these patients.
Conclusion
When data were pooled in a meta-analysis, changes from
baseline statistically favoured exercise over control for FI,
HOMA-IR, TC, LDL-C, triglycerides, VO2 max, WC, and
body fat percentage. Furthermore, a comparison of immedi-
ately post-intervention values also revealed statistical effects
on FI, TC, LDL-C, VO2 max, RHR, and BMI. Compared
with control, exercise also improved the physical function-
ing, general health, social functioning, and mental health do-
mains assessed in the SF-36. Subgroup analyses revealed
that the greatest favourable changes with exercise versus
control were seen in participants who were either over-
weight (FI, HOMA-IR, triglycerides, VO2 max, and WC) or
obese (BMI, body mass, and WC). Post-intervention value
analyses also showed beneficial effects in those who were
overweight (LDL-C, VO2 max, RHR, BMI, WC, and body
fat percentage). Aerobic exercise interventions improved FI,
HOMA-IR, TC, triglycerides, VO2 max, BMI, WC, and
body fat percentage. In contrast, resistance training lowered
HDL-C concentrations and increased BMI, but reduced
WC; post-intervention improvements in HDL-C were also
apparent following resistance exercise. Supervised exercise
interventions improved outcomes more than unsupervised
interventions compared with control. Shorter duration inter-
ventions performed better than longer interventions; im-
proved change from baseline FI, HOMA-IR, TC, LDL-C,
triglycerides, VO2 max, and WC was found in shorter dur-
ation trials, compared with only improved VO2 max in
those > 12weeks. Based on limited available data, we found
no differences between the effects of exercise and diet com-
bined and diet alone. Due to lack of available trials, it was
not possible to compare the effectiveness of exercise versus
diet or exercise and diet combined versus diet.
Although the evidence presented within this systematic
review has largely been drawn from RCTs, a cautious ap-
proach should be adopted when interpreting the findings.
Many of the outcomes presented modest effects and wide
confidence intervals (indicating greater uncertainty). Fur-
thermore, we found the statistical effects in many of the
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vidual trials regardless of their weighting within the ana-
lysis. Using the GRADE approach, we rated the quality of
evidence as very low or low for all primary outcomes. Fu-
ture trials should be rigorously designed and sufficiently
powered so that they are more generalizable to the wider
PCOS population. In order to be more closely aligned
with current treatment recommendations, future studies
should ideally include a dietary component alongside ex-
ercise interventions.Additional files
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